This photo taken in January 2024 shows an intelligent workshop of rice-derived recombinant human serum albumin of Healthgen ...

A Wuhan-based biopharmaceutical company developed technology to synthesize human serum albumin (HSA) from rice, offering a ...

A Chinese biopharmaceutical company has realized large-scale production of rice-derived albumin, turning the staple crop ...

A low-cost biosensor using ZnO thin films and CdTe quantum dots enables fast, accurate vitamin B6 detection for clinical and pharmaceutical use.

Strongrevenueperformance,includingapproximately$1.9millionmilestoneandlicenserevenuerecognizedin2024Up to $7.5 million in grants awarded from ...

Cullinan Therapeutics rebranded from oncology to immunology+oncology, focusing on CD19 TCEs for autoimmune diseases. Check ...

Recent Company Progress Product Commercialization Targets Non-Animal Cell Culture Media Human Serum Albumin: A vital cell culture media component that supports cell growth, survival and function for ...

Q4 2024 Earnings Call Transcript March 26, 2025 Dyadic International, Inc. misses on earnings expectations. Reported EPS is $ ...

Known as F H AB (Fully Human Albumin-Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to ...

Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Chardan Capital in a research note issued on Friday,Benzinga reports. They presently have a ...